SWTX: רווח נקי למניה ב-12 החודשים האחרונים springworkstx.com
Partner manufacturing capacities for oncology drugs are fully utilized, and the equipment remains in ideal condition. The rolling annual earnings per share help assess business stability, where the current parameter equals -3.41. SpringWorks Therapeutics (SWTX) is developing the innovative inhibitor Ogsiveo by investing in precision molecular design. Specialization in rare pathologies with no alternative treatments grants SpringWorks Therapeutics (SWTX) monopolist status and accelerated regulatory approval.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_SWTX_-_SpringWorks-Therapeutics_-_Earnings-per-share-for-the-last-four-quarters "SpringWorks - רווח נקי למניה (EPS TTM) SWTX (תקופה 04.07.2022 - 12.07.2025) | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת SpringWorks Therapeutics
Fundamental asset screening requires separating market noise from actual business performance. This indicator measures net income distributed per share annually, allowing for an objective assessment of equity returns. By analyzing the trend of the rolling 12-month earnings per share, an investor can identify asset overvaluation. For SpringWorks Therapeutics (SWTX), this metric reflects the monetization of developments in rare tumor therapy. The innovative treatment ecosystem for desmoid tumors directly determines the future growth of this indicator.
